Drug intelligence / Profile preview

HGP1607 + HGP1501

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral (inferred From Typical Small Molecule Administration In Early Phase Pk Studies; Explicit Route Not Stated)

Overview

HGP1607 + HGP1501 is an investigational combination of two small molecule drugs developed by Hanmi Pharmaceutical. The combination has been studied in a randomized, open-label, crossover Phase 1 clinical trial to investigate pharmacokinetic drug interactions and safety in healthy male volunteers. The specific mechanisms of action, therapeutic indications, and molecular targets for either component have not been publicly disclosed as of June 2025. Both agents are considered new chemical entities under investigation and are not yet approved for any indication[1][2].

Beyond the preview

Go deeper on HGP1607 + HGP1501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGP1607 + HGP1501.

Explore the full profile